Payment overview · 2025
General Payments
$916.82
37 reported records · 15 companies
Healthcare provider profile · identity verified
Syed M Arshad, MD
Allopathic & Osteopathic Physicians|Internal Medicine|Hematology & Oncology · MARYVILLE, IL · NPI 1154396182
Verified facts
What the public records show
CMS Open Payments records show Syed M Arshad, MD received $916.82 in general payments during 2025 across 37 reported records.
Astellas Pharma US Inc accounted for 18.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 25 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ibrance.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARANESP as an associated drug or biological on 16 records involving 13 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Aranesp by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LUMAKRAS as an associated drug or biological on 304 records involving 190 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Lumakras by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CALQUENCE as an associated drug or biological on 8404 records involving 3935 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Calquence by this doctor in 2024.
Janssen Biotech, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 24 records involving 23 distinct recipient NPIs. Public Medicare Part D data also shows 83 claims for Xarelto by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BOSULIF as an associated drug or biological on 3017 records involving 2109 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Bosulif by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 116 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported IBRANCE as an associated drug or biological on 11505 records involving 4934 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Ibrance by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $165.59 | 18.1% | 4 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $136.87 | 14.9% | 6 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $103.04 | 11.2% | 4 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $78.50 | 8.6% | 4 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $71.28 | 7.8% | 3 | 2025 |
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $62.76 | 6.8% | 3 | 2025 |
| EMD Serono, Inc. | Unresolved — no canonical attribution shown | $62.58 | 6.8% | 3 | 2025 |
| Novocure Inc. | Unresolved — no canonical attribution shown | $38.34 | 4.2% | 2 | 2025 |
| Rigel Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $37.55 | 4.1% | 2 | 2025 |
| Genentech USA, Inc. | Unresolved — no canonical attribution shown | $31.38 | 3.4% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $27.95 | 3.0% | 1 | 2025 |
| SpringWorks Therapeutics, Inc. | Unresolved — no canonical attribution shown | $27.62 | 3.0% | 1 | 2025 |
| Daiichi Sankyo Inc. | Unresolved — no canonical attribution shown | $27.56 | 3.0% | 1 | 2025 |
| ADC THERAPEUTICS AMERICA, INC. | Unresolved — no canonical attribution shown | $23.48 | 2.6% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $22.32 | 2.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $728.22 | 33 |
| Education | $188.60 | 4 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| KEYTRUDA Normalized: keytruda |
Biological | Merck Sharp & Dohme LLC | $111.17 | 5 | 2025 |
Source payment records
|
|||||
| ENHERTU Normalized: enhertu |
Biological, Drug | AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc. | $108.53 | 4 | 2025 |
Source payment records
|
|||||
| VENCLEXTA Normalized: venclexta |
Drug | ABBVIE INC. | $71.28 | 3 | 2025 |
Source payment records
|
|||||
| Xtandi Normalized: xtandi |
Drug | Astellas Pharma US Inc | $49.91 | 2 | 2025 |
Source payment records
|
|||||
| LYNPARZA Normalized: lynparza |
Biological | Merck Sharp & Dohme LLC | $47.95 | 2 | 2025 |
Source payment records
|
|||||
| RYBREVANT Normalized: rybrevant |
Drug | Janssen Biotech, Inc. | $43.75 | 2 | 2025 |
Source payment records
|
|||||
| PADCEV Normalized: padcev |
Biological | PFIZER INC. | $42.40 | 2 | 2025 |
Source payment records
|
|||||
| Optune Lua (NovoTTF-200T) Normalized: optune lua novottf 200t |
Device | Novocure Inc. | $38.34 | 2 | 2025 |
Source payment records
|
|||||
| Gavreto Normalized: gavreto |
Drug | Rigel Pharmaceuticals, Inc. | $37.55 | 2 | 2025 |
Source payment records
|
|||||
| Rezlidhia Normalized: rezlidhia |
Drug | Rigel Pharmaceuticals, Inc. | $37.55 | 2 | 2025 |
Source payment records
|
|||||
| TAVALISSE Normalized: tavalisse |
Drug | Rigel Pharmaceuticals, Inc. | $37.55 | 2 | 2025 |
Source payment records
|
|||||
| IBRANCE Normalized: ibrance |
Drug | PFIZER INC. | $36.10 | 2 | 2025 |
Source payment records
|
|||||
| TUKYSA Normalized: tukysa |
Drug | PFIZER INC. | $36.10 | 2 | 2025 |
Source payment records
|
|||||
| Tecentriq Normalized: tecentriq |
Biological | Genentech USA, Inc. | $31.38 | 1 | 2025 |
Source payment records
|
|||||
| PLUVICTO Normalized: pluvicto |
Drug | Novartis Pharmaceuticals Corporation | $27.95 | 1 | 2025 |
Source payment records
|
|||||
| OGSIVEO Normalized: ogsiveo |
Drug | SpringWorks Therapeutics, Inc. | $27.62 | 1 | 2025 |
Source payment records
|
|||||
| KEYTRUDA QLEX Normalized: keytruda qlex |
Biological | Merck Sharp & Dohme LLC | $25.83 | 1 | 2025 |
Source payment records
|
|||||
| WELIREG Normalized: welireg |
Drug | Merck Sharp & Dohme LLC | $25.70 | 1 | 2025 |
Source payment records
|
|||||
| ZYNLONTA Normalized: zynlonta |
Drug | ADC THERAPEUTICS AMERICA, INC. | $23.48 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $22.32 | 1 | 2025 |
Source payment records
|
|||||
| IMFINZI Normalized: imfinzi |
Biological | AstraZeneca Pharmaceuticals LP | $22.07 | 1 | 2025 |
Source payment records
|
|||||
| Vyloy Normalized: vyloy |
Drug | Astellas Pharma US Inc | $21.73 | 1 | 2025 |
Source payment records
|
|||||
| BALVERSA Normalized: balversa |
Drug | Janssen Biotech, Inc. | $19.01 | 1 | 2025 |
Source payment records
|
|||||
| ERLEADA Normalized: erleada |
Drug | Janssen Biotech, Inc. | $19.01 | 1 | 2025 |
Source payment records
|
|||||
| INLYTA Normalized: inlyta |
Drug | PFIZER INC. | $17.04 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| IBRANCE ibrance |
2025 | Ibrance | 2024 | 54 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | ARANESP open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 13 recipient NPIs · example record 1227128438 |
Aranesp · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | LUMAKRAS open payments reported associated product |
CMS Open Payments — General Payments 304 supporting records · 190 recipient NPIs · example record 1226871991 |
Lumakras · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | CALQUENCE open payments reported associated product |
CMS Open Payments — General Payments 8404 supporting records · 3935 recipient NPIs · example record 1206131382 |
Calquence · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Janssen Biotech, Inc. Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 24 supporting records · 23 recipient NPIs · example record 1174259978 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
83 | 18 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | BOSULIF open payments reported associated product |
CMS Open Payments — General Payments 3017 supporting records · 2109 recipient NPIs · example record 1228795613 |
Bosulif · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
116 | 23 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | IBRANCE open payments reported associated product |
CMS Open Payments — General Payments 11505 supporting records · 4934 recipient NPIs · example record 1228794164 |
Ibrance · 2024 Exact normalized brand match · 1 Part D row |
54 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Anastrozole | Anastrozole | 307 | 87 |
| Tamoxifen Citrate | Tamoxifen Citrate | 132 | 45 |
| Eliquis | Apixaban | 116 | 23 |
| Ondansetron Odt | Ondansetron | 96 | 62 |
| Xarelto | Rivaroxaban | 83 | 18 |
| Dexamethasone | Dexamethasone | 80 | 29 |
| Potassium Chloride | Potassium Chloride | 76 | 28 |
| Prednisone | Prednisone | 70 | 16 |
| Lidocaine-Prilocaine | Lidocaine/Prilocaine | 62 | 46 |
| Brukinsa | Zanubrutinib | 57 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 55 | 15 |
| Hydroxyurea | Hydroxyurea | 55 | 14 |
| Gabapentin | Gabapentin | 54 | 11 |
| Ibrance | Palbociclib | 54 | suppressed |
| Acyclovir | Acyclovir | 41 | 12 |
| Folic Acid | Folic Acid | 39 | suppressed |
| Abiraterone Acetate | Abiraterone Acetate | 33 | suppressed |
| Furosemide | Furosemide | 31 | suppressed |
| Allopurinol | Allopurinol | 29 | 12 |
| Megestrol Acetate | Megestrol Acetate | 28 | 18 |
| Revlimid | Lenalidomide | 28 | suppressed |
| Levothyroxine Sodium | Levothyroxine Sodium | 27 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 26 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 23 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 23 | 12 |
| Alprazolam | Alprazolam | 21 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 21 | 11 |
| Lenalidomide | Lenalidomide | 20 | suppressed |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 20 | 11 |
| Letrozole | Letrozole | 18 | suppressed |
| Levofloxacin | Levofloxacin | 18 | 16 |
| Tramadol Hcl | Tramadol Hcl | 18 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 18 | suppressed |
| Aranesp | Darbepoetin Alfa In Polysorbat | 17 | suppressed |
| Omeprazole | Omeprazole | 16 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 15 | suppressed |
| Lumakras | Sotorasib | 15 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 14 | suppressed |
| Klor-Con M20 | Potassium Chloride | 14 | suppressed |
| Calcitriol | Calcitriol | 13 | suppressed |
| Fentanyl | Fentanyl | 13 | suppressed |
| Anagrelide Hcl | Anagrelide Hcl | 12 | suppressed |
| Calquence | Acalabrutinib Maleate | 12 | suppressed |
| Azithromycin | Azithromycin | 11 | 11 |
| Bosulif | Bosutinib | 11 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $916.82 · 37 records | Astellas Pharma US Inc | BALVERSA, ENHERTU, ERLEADA, Gavreto, IBRANCE, IMFINZI, INLYTA, KEYTRUDA, KEYTRUDA QLEX, LYNPARZA, OGSIVEO, Optune Lua (NovoTTF-200T), PADCEV, PLUVICTO, REPATHA, RYBREVANT, Rezlidhia, TAVALISSE, TUKYSA, Tecentriq, VENCLEXTA, Vyloy, WELIREG, Xtandi, ZYNLONTA | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ibrance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Amgen Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error